Celgene to stop blood cancer trial due to high death rates

[riky]

Celgene to stop blood cancer trial due to high death rates

(Reuters) - Celgene Corp said it will stop a late-stage trial of its blood cancer drug, Revlimid, after it observed a higher number of deaths in elderly leukemia patients taking the drug compared with those on another treatment. Revlimid, with 2012 sales of $3.8 billion, is Celgene's flagship blood cancer drug and is already approved for use in various types of blood cancer, including multiple myeloma and mantle cell lymphoma. Celgene shares were down 2.7 percent at $132.98 on Thursday afternoon on the Nasdaq. Over the past 12 months, the shares have nearly doubled. ...

Source: You are not allowed to view links. Register or Login